Table 1. Studies comparing LDLT and DDLT for HCC.

Authors (Year)	Center	Study period	Treatment	n	OS (3 y) (%)	P	RFS (3 y) (%)	P	RR (3 y) (%)	P	Waiting periods (mo)	P	Vascular invasion (%)	P	Poorly differentiated or Edmonson grade 3, 4 (%)	P	Beyond Milan (%)	P
Gondolesi [2004]	Mount Sinai Hospital, USA	1998–2002	LDLT	36	60 (2 y)	0.20	74 (2 y)	0.30	17 (5 y)	–	2.0	0.0001	58	–	17	–	–	–
			DDLT	165	70		83		–		14.8		–		–		–
Hwang [2005]	Four institutions, Korea	1992–2002	LDLT	237	73	0.04	80 (2 y)	0.77	–	–	–	–	15	–	37	–	29	0.69
			DDLT	75	61		82		–		–		11		36		27
Lo* [2007]	Queen Mary Hospital, China	1995–2004	LDLT	43	80	0.19	–	–	29	0.03	0.9	<0.0010	35	0.190	19	0.46	26	0.76
			DDLT	17	94		–		0		3.5		18		18		29
Fisher* [2007]	A2ALL	1998–2003	LDLT	58	67	0.91	58	0.38	26	0.002	3.1	<0.0001	22	0.170	15	0.26	62	0.05
			DDLT	34	63		62		0		12.0		10		3		41
Sotiropoulos [2007]	University Hospital Essen, Germany	1998–2006	LDLT	45	63	0.17	–	–	10	0.87	–	–	–	–	–	–	49	0.70
			DDLT	55	67		–		19		–		–		–		55
Di Sandro [2009]	Niguarda Ca’ Granda Hospital, Italy	2000–2007	LDLT	25	77	N.S.	96	N.S.	4	–	3.5	0.0004	20	N.S.	28	N.S.	40	N.S.
			DDLT	154	83		91		10		13.2		14		27		31
Vakili* [2009]	Lahey Clinic Medical Center, USA	1999–2007	LDLT	28	81 (5 y)	0.023	–	–	29	<0.05	–	–	46	–	10	–	25	–
			DDLT	74	58		–		12				–		–		–
Li [2010]	West China Hospital, China	2005–2009	LDLT	38	53	0.57	42	0.79	–	–	–	–	47	0.410	13	0.18	79	0.22
			DDLT	101	50		41						40		20		68
Bhangui [2011]	Paul Brousse Hospital, France	2000–2009	LDLT	36	80	0.36	–	–	11	0.94	2.6	0.0001	–	–	–	–	27	0.44
			DDLT	120	82		–		11		7.9		–		–		21
Sandhu [2012]	Tronto General Hospital, Canada	1996–2009	LDLT	58	75	0.62	75	0.82	11	0.54	3.1	0.0030	28	0.96	5.8	0.10	58	0.33
			DDLT	287	80		75		15		5.3		29		14.2		51
Kulik* [2012]	A2ALL	1998–2010	LDLT	100	59 (5 y)	0.27	66	0.05	38 (5 y)	0.0004	–	–	23	0.066	16	0.97	56	0.0003
			DDLT	97	66		81		11		–		12		19		45
Park* [2014]	Seoul National University, Samsung Medical Center, Korea	1999–2010	LDLT	166	–	–	81	0.044	–	–	–	–	18	0.038	45	0.18	–	–
			DDLT	50	–		94		–		–		6		34		–
Ninomiya [2015]	Kyusyu University, Japan; Mount Sinai Hospital, USA	2002–2010	LDLT	133	87	<0.0001	–	–	14	0.64	1.4	<0.0001	40	0.920	29	<0.0001	41	0.16
			DDLT	362	73		–		14		6.3		40		10		34
Chen [2015]	West China Hospital, China	2005–2013	LDLT	75	68	0.51	71	0.86	–	–	0.8	<0.0010	41	0.140	12	0.69	48	–
			DDLT	180	71		73		–		1.5		31		16		44
Zhenhua [2015]	China Liver Transplant Registry, China	1999–2009	LDLT	389	70	<0.01	64	<0.01	–	–	–	–	–	–	–	–	–	–
			DDLT	6,471	54		49		–		–		–		–		–

*, studies supporting higher HCC recurrence in LDLT. LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrent-free survival; RR, recurrence rate; A2ALL, Adult-to-Adult Living Donor Liver transplantation Cohort Study; N.S., not significant.